Table 1.
Antimicrobial susceptibility testing results of clinical CRE strains (MICs, mg/L).
| Antimicrobial agent | All CRE (n = 935) | KPC-producers (n = 482) | NDM-producers (n = 334) | OXA-48-like producers (n = 68) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC | MIC50 | MIC90 | %R | %S | MIC50 | MIC90 | %R | %S | MIC50 | MIC90 | %R | %S | MIC50 | MIC90 | %R | %S | |
| range | |||||||||||||||||
| Piperacillin | 4->256 | >256 | >256 | 98.9 | 0.9 | >256 | >256 | 99.4 | 0.2 | >256 | >256 | 99.7 | 0.3 | >256 | >256 | 100 | 0 |
| Cefoperazone-sulbactam | 1->128 | >128 | >128 | 98.3 | 1.2 | >128 | >128 | 98.1 | 1.2 | >128 | >128 | 99.4 | 0 | >128 | >128 | 100 | 0 |
| Piperacillin-tazobactam | 2->256 | >256 | >256 | 97.2 | 1.5 | >256 | >256 | 98.8 | 0.6 | >256 | >256 | 99.4 | 0 | >256 | >256 | 100 | 0 |
| Cefazolin | 32->32 | >32 | >32 | 100 | 0 | >32 | >32 | 100 | 0 | >32 | >32 | 100 | 0 | >32 | >32 | 100 | 0 |
| Cefuroxime | 2->64 | >64 | >64 | 99.9 | 0.1 | >64 | >64 | 100 | 0 | >64 | >64 | 100 | 0 | >64 | >64 | 100 | 0 |
| Ceftazidime | 0.5->32 | >32 | >32 | 98.6 | 0.7 | >32 | >32 | 98.1 | 0.8 | >32 | >32 | 99.7 | 0 | >32 | >32 | 100 | 0 |
| Ceftriaxone | 0.12-64 | >32 | >32 | 99.4 | 0.6 | >32 | >32 | 99.4 | 0.6 | >32 | >32 | 99.7 | 0.3 | >32 | >32 | 100 | 0 |
| Ceftazidime-avibactam | 0.25->32 | 2 | >32 | 38.6 | 61.4 | 2 | 4 | 0 | 100 | >32 | >32 | 100 | 0 | 0.5 | 4 | 0 | 100 |
| Cefepime | 0.25->32 | >32 | >32 | 98.1 | 0.9 | >32 | >32 | 97.9 | 1 | >32 | >32 | 99.4 | 0 | >32 | >32 | 100 | 0 |
| Cefmetazole | 1->64 | >64 | >64 | 92.7 | 4.5 | >64 | >64 | 92.3 | 5.6 | >64 | >64 | 97.6 | 1.2 | 64 | >64 | 73.5 | 13.2 |
| Aztreonam | 0.25->128 | >128 | >128 | 93.2 | 4.2 | >128 | >128 | 99 | 0.8 | >128 | >128 | 85.3 | 7.8 | >128 | >128 | 100 | 0 |
| Ertapenem | 0.25->32 | >32 | >32 | 98.9 | 1 | >32 | >32 | 99 | 1 | >32 | >32 | 99.7 | 0.3 | >32 | >32 | 100 | 0 |
| Imipenem | 0.12->16 | >16 | >16 | 96.1 | 2.1 | >16 | >16 | 99.2 | 0.6 | 16 | >16 | 99.4 | 0.3 | >16 | >16 | 73.5 | 17.6 |
| Meropenem | 0.12->16 | >16 | >16 | 97 | 1.9 | >16 | >16 | 98.1 | 1.5 | >16 | >16 | 99.7 | 0.3 | >16 | >16 | 85.3 | 4.4 |
| Amikacin | 1->128 | 16 | >128 | 49.6 | 50.1 | >128 | >128 | 69.7 | 29.9 | 1 | >128 | 13.8 | 86.2 | >128 | >128 | 100 | 0 |
| Gentamicin | 1->128 | 128 | >128 | 67.9 | 31.8 | >128 | >128 | 83.8 | 16 | 1 | 128 | 40.4 | 59.3 | >128 | >128 | 100 | 0 |
| Ciprofloxacin | 0.06->8 | >8 | >8 | 78.4 | 19 | >8 | >8 | 95.6 | 3.7 | 8 | >8 | 53.6 | 41.3 | >8 | >8 | 100 | 0 |
| Levofloxacin | 0.06->16 | >16 | >16 | 76.3 | 22.9 | >16 | >16 | 94.6 | 4.8 | 4 | >16 | 49.4 | 49.7 | >16 | >16 | 100 | 0 |
| Trimethoprim- Sulfamethoxazole | 0.25->32 | 32 | >32 | 54.8 | 45.2 | 1 | >32 | 47.9 | 52.1 | >32 | >32 | 54.5 | 45.5 | >32 | >32 | 100 | 0 |
| Polymyxin B | 0.125->16 | 0.25 | 1 | 4 | 95.8 | 0.25 | 1 | 4.4 | 95.4 | 0.25 | 1 | 3.6 | 96.1 | 0.5 | 0.5 | 1.5 | 98.5 |
| Nitrofurantoin | 4->128 | >128 | >128 | 64.1 | 18.8 | >128 | >128 | 92.9 | 4.6 | 64 | >128 | 22.8 | 41.9 | 128 | >128 | 64.7 | 8.8 |
| Tigecycline | 0.12–8 | 0.5 | 2 | 0.3 | 98.4 | 0.5 | 2 | 0.4 | 97.7 | 0.5 | 1 | 0.3 | 99.1 | 1 | 2 | 0 | 100 |
CRE, carbapenem-resistant Enterobacteriaceae; MIC50/90, 50%/90% minimum inhibitory concentration; %R, % of isolates resistant; %S, % of isolates susceptible.